HUGE.CN - FSD Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.345
-0.025 (-6.76%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.370
Open0.000
Bid0.345 x 0
Ask0.345 x 0
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume24,957,700
Market Cap463.514M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.012
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile6 days ago

    InvestmentPitch Media Video Discusses Licensed Cannabis Producer FSD Pharma's Appointment of High Level Government Relations Executive, David Urban to Board of Directors - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - November 15, 2018) - FSD Pharma Inc. (CSE: HUGE) (FSE: 0K9) (OTCQB: FSDDF) has appointed David Urban to the company's Board of Directors. Mr. Urban is an accomplished business and government relations executive, advising companies ranging in size from start-ups to Fortune 100 on interaction with government.InvestmentPitch.com has produced a "video" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "FSD Pharma" in ...

  • FSD Pharma adds David Urban to Board of Directors
    CNW Group7 days ago

    FSD Pharma adds David Urban to Board of Directors

    Mr. Urban is an accomplished business and government relations executive. In the field of politics, Mr. Urban has achieved success serving as an advisor to campaigns at the highest levels, including the President of the United States, the United States Senate and United States House of Representatives.

  • Business Wire7 days ago

    FSD Pharma Adds David Urban to Board of Directors

    Mr. Urban is an accomplished business and government relations executive. In the field of politics, Mr. Urban has achieved success serving as an advisor to campaigns at the highest levels, including the President of the United States, the United States Senate and United States House of Representatives.

  • GlobeNewswire8 days ago

    New Green Frontier 2018; Gravitas Financial Inc.’s inaugural cannabis investor conference announces Gene Simmons as keynote speaker

    TORONTO, Nov. 13, 2018 -- Today, New Green Frontier, an invite-only, cannabis investor conference, is pleased to announce that Gene Simmons, legendary rock star, Chief.

  • CNW Group8 days ago

    IIROC Trade Resumption - HUGE

    VANCOUVER , Nov. 13, 2018 /CNW/ - Trading resumes in: Company: FSD Pharma Inc. CSE Symbol: HUGE Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in ...

  • Business Wire8 days ago

    FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint

    FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations. As of November 7, 2018, FV Pharma also received license amendments approving all of the remaining 25,000 square feet currently built out for additional grow and operations.

  • FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint
    CNW Group8 days ago

    FSD Pharma Receives License to Sell to Other Licensed Producers and Expands Growth Production Footprint

    TORONTO, Nov. 13, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. ("FV Pharma") under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations. As of November 7, 2018, FV Pharma also received license amendments approving all of the remaining 25,000 square feet currently built out for additional grow and operations.

  • CNW Group8 days ago

    IIROC Trading Halt - HUGE

    VANCOUVER , Nov. 13, 2018 /CNW/ - The following issues have been halted by IIROC: Company: FSD Pharma Inc. CSE Symbol: HUGE Reason: At the request of the Company Pending News Halt Time (ET): 8:00 AM IIROC ...

  • CNW Group9 days ago

    IIROC Trading Halt - HUGE

    VANCOUVER , Nov. 12, 2018 /CNW/ - The following issues have been halted by IIROC: Company: FSD PHARMA INC. CSE Symbol: HUGE Reason:  At the request of the Company Pending News Halt Time (ET): 14:08 PM ...

  • GlobeNewswire15 days ago

    SciCann Therapeutics Announces Positive ISA Report for “Steady Stomach” CBD Combination Therapy Patent

    SciCann Therapeutics Inc. (“SciCann”) announced today it has received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy patent, the basis of its “Steady Stomach” product. The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive. SciCann’s strategic partner for the development and commercialization of the “Steady Stomach” product is FSD Pharma Inc. (“FSD Pharma”) (CSE:HUGE) (FSDDF) (0K9.F), which under the terms of the agreement between the companies holds exclusive manufacturing and distribution rights for the product in Canada.

  • FSD Pharma Announces Positive ISA Report for "Steady Stomach" CBD Combination
    CNW Group15 days ago

    FSD Pharma Announces Positive ISA Report for "Steady Stomach" CBD Combination

    TORONTO, Nov. 6, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma") (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) announced today that its strategic R&D partner, SciCann Therapeutics Inc. ("SciCann") received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy, the basis of its "Steady Stomach" product. The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive.

  • Business Wire15 days ago

    FSD Pharma Announces Positive ISA Report for “Steady Stomach” CBD Combination

    FSD Pharma Inc. (“FSD Pharma”) (HUGE.CN) (FSDDF) (0K9.F) announced today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”) received a positive International Search Authority (ISA) report from the Patent Cooperation Treaty (PCT) for its SCN-001 cannabidiol (CBD) combination therapy, the basis of its “Steady Stomach” product. The comprehensive prior art search performed by ISA for the PCT/IL2018/051000 patent application by SciCann led the agency to conclude that the enhanced CBD combination therapy claimed by the patent application is novel and inventive.

  • FSD Pharma Announces Launch of IBS Clinical Study
    CNW Group21 days ago

    FSD Pharma Announces Launch of IBS Clinical Study

    TORONTO, Oct. 31, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or "FSD") (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics ("SciCann"). The study is designed to test the safety and efficacy of SciCann's proprietary "Steady Stomach" cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy results from a preclinical study in rodent models which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone.

  • Business Wire21 days ago

    FSD Pharma Announces Launch of IBS Clinical Study

    FSD Pharma Inc. (“FSD Pharma” or “FSD”) (HUGE.CN) (FSDDF) (0K9.F) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic R&D partner, SciCann Therapeutics (“SciCann”). The study is designed to test the safety and efficacy of SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome (IBS) patients. This study follows the previously reported efficacy results from a preclinical study in rodent models which demonstrated a three-fold increased efficacy in lowering abdominal inflammation levels with the advanced combination product as compared to CBD alone.

  • GlobeNewswire22 days ago

    Bloomberg Interviews FSD Pharma for Cannabis Shortage Feature -- CFN Media

    SEATTLE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE:HUGE) (FSDDF) (0K9.F) and the cannabis shortage following legalization. Bloomberg recently interviewed the company to address the cannabis shortage issue. Canada may have legalized adult-use cannabis on October 17, but that doesn’t mean consumers are able to purchase the drug. According to Bloomberg, there are widespread shortages across the country, despite an ample supply of licensed producers awaiting approval from Health Canada.

  • FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-Chairman and Zeeshan Saeed as President
    CNW Group23 days ago

    FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-Chairman and Zeeshan Saeed as President

    TORONTO, Oct. 29, 2018 /CNW/ - The Board of Directors of FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) is pleased to announce the appointment of Dr. Raza Bokhari as interim CEO and Co-Chairman of the Board of Directors, replacing Thomas Fairfull. Dr. Bokhari brings a wealth of knowledge in global business and healthcare services. Physician turned entrepreneur, Dr. Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies.

  • Business Wire23 days ago

    FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-Chairman and Zeeshan Saeed as President

    The Board of Directors of FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) is pleased to announce the appointment of Dr. Raza Bokhari as interim CEO and Co-Chairman of the Board of Directors, replacing Thomas Fairfull. Dr. Bokhari brings a wealth of knowledge in global business and healthcare services. Physician turned entrepreneur, Dr. Bokhari has over the past several years developed outstanding expertise in aggregating and accelerating life sciences and healthcare services companies.

  • Marijuana Shortages Abound in Canada Amid Application Flood
    Bloomberg26 days ago

    Marijuana Shortages Abound in Canada Amid Application Flood

    “We’re biting our nails and I think our shareholders are biting their nails too,” said Anthony Durkacz, director at FSD Pharma Inc., an Ontario-based producer that received its cultivation license a year ago and is still waiting for its sales license. The process of getting a sales license from Health Canada is onerous, according to Durkacz. After receiving a cultivation license, a grower must produce two full crops, send them off for testing, get its sales software audited, and then submit a completed application for the sales license, which can take up to 341 days to process, he said.

  • GlobeNewswire26 days ago

    FSD Pharma Doubles Down on Cannabinoid Therapeutics with Therapix Acquisition -- CFN Media

    SEATTLE, Oct. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE:HUGE) (FSDDF) (0K9.F). The company recently announced a binding letter of intent to acquire Therapix Biosciences Ltd. The move bolsters its high-margin pharmaceutical business at the same time as it ramps up its production footprint. Canada’s cannabis industry could experience a dramatic windfall with the legalization of recreational cannabis in October, but many cannabis companies are looking beyond the borders for opportunities.

  • FSD Pharma announces issuance of cannabis license under Excise Act
    CNW Group27 days ago

    FSD Pharma announces issuance of cannabis license under Excise Act

    TORONTO, Oct. 25, 2018 /CNW/ - FSD Pharma Inc. ("FSD Pharma" or the "Company") (CSE:HUGE.CN - News) (OTCQB:FSDDF - News) (FRA:0K9.F - News) announced today that the Company's application for a cannabis license under the Excise Tax Act has been conditionally approved by the Canada Revenue Agency (the "CRA") and is effective as of October 17, 2018. The issuance of a cannabis license by the CRA is a requirement to sell cannabis and is a prerequisite to obtaining a sales license under the Cannabis Act. Zeeshan Saeed, EVP, Director and Co-Founder of FSD Pharma stated, "The granting of this cannabis license by the CRA brings the Company one step closer to selling to the marketplace as we approach the granting of our sales license from Health Canada.

  • Business Wire27 days ago

    FSD Pharma Announces Issuance of Cannabis License under Excise Act

    FSD Pharma Inc. (“FSD Pharma” or the “Company”) (HUGE.CN) (FSDDF) (0K9.F) announced today that the Company’s application for a cannabis license under the Excise Tax Act has been conditionally approved by the Canada Revenue Agency (the “CRA”) and is effective as of October 17, 2018. The issuance of a cannabis license by the CRA is a requirement to sell cannabis and is a prerequisite to obtaining a sales license under the Cannabis Act. Zeeshan Saeed, EVP, Director and Co-Founder of FSD Pharma stated, “The granting of this cannabis license by the CRA brings the Company one step closer to selling to the marketplace as we approach the granting of our sales license from Health Canada.

  • Newsfile28 days ago

    InvestmentPitch Media Video Discusses FSD Pharma 's Pending Acquisition of Therapix Biosciences a Clinical-Stage Pharmaceutical Company Developing Unique Cannabinoid Technologies - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 24, 2018) - FSD Pharma Inc. (CSE: HUGE) (FSE:0K9) (OTCQB: FSDDF) has signed a binding letter of intent to acquire Therapix Biosciences Ltd. (NASDAQ:TRPX), a specialty clinical-stage pharmaceutical company developing unique cannabinoid technologies. Therapix (www.therapixbio.com) is currently repurposing an FDA-approved cannabinoid for the treatment of central nervous system disorders, sleep disorders, pain management, mild cognitive impairment, traumatic brain injury and infectious diseases.InvestmentPitch.com has produced a "video" which ...

  • CNW Group29 days ago

    IIROC Trade Resumption - HUGE

    VANCOUVER , Oct. 23, 2018 /CNW/ - Trading resumes in: Company: FSD Pharma Inc. Subordinate Voting Shares CSE Symbol: HUGE Resumption (ET): 10:00 AM IIROC can make a decision to impose a temporary suspension ...

  • FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a Nasdaq Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments to Create Medical Cannabis Industry Innovator
    CNW Grouplast month

    FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a Nasdaq Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments to Create Medical Cannabis Industry Innovator

    CSE: HUGE OTCQB: FSDDF FRA: 0K9 Transaction combines two highly complementary businesses; the significant production and distribution of medical and recreational products by FSD Pharma, and the premium ...

  • Business Wirelast month

    FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a NASDAQ Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments, to Create Medical Cannabis Industry Innovator

    FSD Pharma Inc. signs binding LOI to acquire Therapix Biosciences Ltd., a NASDAQ traded company focusing on the development of cannabinoid-based treatments to create medical cannab